Where MedTech Is Attracting PE Attention With Less FDA Burden

Overview

PE is getting into component manufacturing and device servicing opportunities, where US Food and Drug Administration (FDA) distinctions are creating a compelling case for MedTech investment – if those regulatory advantages hold post-close.

Not every MedTech business carries the same regulatory obligations. Two MedTech companies can serve the same customers and markets but face very different levels of FDA scrutiny depending on their role in the medical device supply chain – a distinction that is creating attractive opportunities for private equity.

Component manufacturers and companies that service or refurbish medical devices are emerging as particularly appealing targets. They benefit from demand across the MedTech market without necessarily facing the same direct FDA requirements as finished-device manufacturers or remanufacturers. For sponsors, that combination can offer a compelling way to capture MedTech growth with less regulatory complexity.